To achieve this objective, our aim is to synthesize a significant amount of 131I-labeled YZHER2: V2 and assess its efficacy as a TRNT agent for ovarian carcinoma with HER2-positive expression. The gene discussed is ERBB2; the disease is ovarian carcinoma.